MarketCap
Facebook
X
Telegram
Danaher Corporation Market Cap | DHR
As of August 03, 2026 Danaher Corporation has a market cap of $ 139 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 B | 152 B | 183 B | 181 B | 196 B | 155 B | 121 B | 76.4 B | 70.7 B | 55.5 B | 45.9 B | 43.9 B | 39.7 B | 31.5 B | 26.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 196 B | 26.9 B | 102 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Centogene N.V.
CNTG
|
10.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
NeoGenomics
NEO
|
1.48 B | $ 15.29 | -3.72 % | $ 1.96 B | USA |
 |
Neogen Corporation
NEOG
|
2.51 B | $ 12.04 | 4.42 % | $ 2.62 B | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Natera
NTRA
|
30.5 B | $ 267.76 | -0.7 % | $ 36.6 B | USA |
 |
OPKO Health
OPK
|
1.04 B | $ 1.32 | -1.12 % | $ 991 M | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 416.3 | 2.6 % | $ 29.2 B |  Schweiz |
 |
Koninklijke Philips N.V.
PHG
|
30.3 B | $ 26.3 | -0.53 % | $ 24.9 B |  Niderland |
 |
Aspira Women's Health
AWH
|
3.03 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
4.03 M | - | -61.36 % | $ 2.46 M | USA |
 |
Personalis
PSNL
|
431 M | $ 12.66 | 3.09 % | $ 1.13 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 16.77 | 1.21 % | $ 706 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Celcuity
CELC
|
5.37 B | $ 86.38 | -1.44 % | $ 4.04 B | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 1.98 | 0.51 % | $ 131 M | USA |
 |
Global Cord Blood Corporation
CO
|
304 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
133 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
404 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 43.71 | 14.72 % | $ 2.33 B | USA |
 |
Waters Corporation
WAT
|
19.7 B | $ 377.31 | -0.79 % | $ 22.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
10.1 B | $ 163.57 | -1.19 % | $ 12.8 B |  Irlanda |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.08 B | - | - | $ 2.69 B | USA |
 |
Exagen
XGN
|
70.1 M | $ 4.53 | -3.0 % | $ 97.7 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 233.01 | -0.58 % | $ 25.9 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
7.19 M | $ 1.49 | -6.28 % | $ 3.42 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
DarioHealth Corp.
DRIO
|
32.8 M | $ 7.27 | -1.76 % | $ 29 M | Israel |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 3.42 | -3.93 % | $ 111 K | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.44 | -7.69 % | $ 1.92 M | USA |
 |
DexCom
DXCM
|
25.5 B | $ 83.45 | 11.95 % | $ 32.6 B | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
237 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
7.78 M | - | -39.35 % | $ 313 K | USA |
 |
Renalytix AI plc
RNLX
|
22.7 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Syneos Health
SYNH
|
9.41 B | - | - | $ 4.46 B | USA |